EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α‐Positive Advanced Ovarian Cancer

Yongsheng Li iD, Li Yuan iD, Ge Lou, Hongbing Cai, Yuzhi Li, Fenghu Li, Li Wang, Xingtao Long, Yi Gong, Chaonan Zhu, Li Li, June Xu und 1 weitere

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71704 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, online erschienen am 21.05.2026. Verfasst von Yongsheng Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing University Cancer Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Folate Receptor 1, Ovarian Neoplasms, Maytansine, Immunoconjugates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hangzhou Zhongmei Huadong Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Folate receptor α (FRα) is a glycosylphosphatidylinositol‐anchored protein that facilitates folate transport and has emerged as a promising therapeutic target for ovarian cancer, particularly due to its association with tumor progression. This Phase I study investigated the safety, tolerability, pharmacokinetics, and preliminary efficacy of mirvetuximab soravtansine (MIRV), an antibody‐drug conjugate targeting folate receptor α (FRα), in Chinese patients with FRα‐overexpressed platinum‐resistant ovarian cancer.

Methods

This study enrolled 19 Chinese patients with previously treated FRα‐overexpressed ovarian cancer in the dose escalation phase (5 mg/kg, n = 4; 6 mg/kg, n = 3) and dose expansion phase ( n = 12). MIRV was administered in escalating doses from 5 to 6 mg/kg (adjusted ideal body weight), following a 3 + 3 dose‐escalation design. The trial is registered with chinadrugtrials.org.cn (CTR20211876).

Results

Median treatment exposure were 9.9 weeks for the 5 mg/kg cohort ( n = 4) and 13.1 weeks for the 6 mg/kg cohort ( n = 15). The most common grade ≥ 3 adverse events were decreased platelet count (21.1%), decreased lymphocyte count (15.8%), and anemia (15.8%). The plasma concentration‐time and pharmacokinetic profiles of MIRV and the total antibody were generally comparable after the first and third doses. Pharmacokinetic analysis revealed a median time to maximum concentration ( T max ) of 3.33 h, mean terminal half‐life ( T 1/2 ) of 118 h, and geometric mean maximum concentration ( C max ) of 137.07 μg/mL. MIRV exposures were comparable to those reported in Caucasian patients. No anti‐drug antibodies were detected. Among 15 efficacy‐evaluable patients with high‐grade serous ovarian cancer, the objective response rate was 26.7%, with partial responses in four patients and stable disease in seven patients.

Conclusions

MIRV showed anticipated pharmacokinetics, safety, tolerability, and efficacy profiles in Chinese patients with FRα‐positive platinum‐resistant ovarian cancers, supporting its potential as a targeted therapeutic agent for this patient population. Trial Registration The trial is registered with chinadrugtrials.org.cn (CTR20211876)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Folate Receptor 1Ovarian NeoplasmsMaytansineImmunoconjugatesAntibodies, Monoclonal, HumanizedHumansFemaleMiddle AgedAdultAgedChinaTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

antibody drug conjugatemirvetuximab soravtansinerefractory ovarian cancertargeted therapy

Substanzen

mirvetuximab soravtansineFolate Receptor 1MaytansineImmunoconjugatesAntibodies, Monoclonal, HumanizedFOLR1 protein, human

Autor:innen und Institutionen

  • Chongqing University Cancer Hospital, Chongqing, China.
  • Harbin Medical University Cancer Hospital, Harbin, China.
  • Zhongnan Hospital of Wuhan University, Wuhan, China.
  • The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Guizhou Provincial Cancer Hospital, Guiyang, China.
  • Henan Cancer Hospital, Zhengzhou, China.

ORCID-Profile: Yongsheng Li, Li Yuan

Förderung

  • Hangzhou Zhongmei Huadong Pharmaceutical Company

Zitieren

APA

Li, Y., Yuan, L., Lou, G., Cai, H., Li, Y., Li, F., Wang, L., Long, X., Gong, Y., Zhu, C., Li, L., Xu, J., & Zhou, Q. (2026). Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α‐Positive Advanced Ovarian Cancer. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71704

Vancouver

Li Y, Yuan L, Lou G, Cai H, Li Y, Li F, et al. Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α‐Positive Advanced Ovarian Cancer. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71704

BibTeX
@article{Li2026,
  author = {Li, Yongsheng and Yuan, Li and Lou, Ge and Cai, Hongbing and Li, Yuzhi and Li, Fenghu and Wang, Li and Long, Xingtao and Gong, Yi and Zhu, Chaonan and Li, Li and Xu, June and Zhou, Qi},
  title = {Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α‐Positive Advanced Ovarian Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71704}
}
Kostenlos starten →